HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Musat, M Articles by Grossman, A B Search for Related Content PubMed PubMed Citation Articles by Musat, M Articles by Grossman, A B

M Muat^1,2, M Korbonits¹, B Kola¹, N Borboli¹, M R Hanson¹, A M Nanzer¹, J Grigson³, S Jordan³, D G Morris¹, M Gueorguiev¹, M Coculescu², S Basuand⁴ and A B Grossman¹

¹ Department of Endocrinology, St Bartholomew’s Hospital, London EC1A 7BE, UK
² Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
³ Department of Histopathology, St Bartholomew’s Hospital, London EC1A 7BE, UK
⁴ Institute of Cancer, Centre for Molecular Oncology, Cell Survival Signalling Group, Queen Mary College, Charterhouse Square, London, EC1M 6BQ, UK

(Requests for offprints should be addressed to A B Grossman; Email: a.b.grossman{at}qmul.ac.uk)

Pituitary tumours have previously been shown to harbour several abnormalities that cause deregulation of the cell cycle, particularly down-regulation of expression of the cyclin-dependent kinase inhibitor p27. However, it has been unclear whether these are the primary initiating events, or are secondary to other more proximate alterations in signalling pathways. In other cellular systems the Akt signalling pathway has been associated with downstream modulation of cell-cycle control. The aim of the present study was to test the hypothesis that Akt signalling is enhanced in pituitary tumours, and to see if changes in Akt expression are related to previous findings on low expression levels of the nuclear cell-cycle inhibitor p27 in pituitary tumours. We examined normal and adenomatous human pituitary tissue for mRNA and protein expression of Akt1, Akt2 and p27, and the activation of Akt, as well the phosphatase involved in the inactivation of Akt, phosphatase and tensin homologue deleted on chromosome 10 (PTEN). In pituitary adenomas Akt1 and Akt2 mRNA were found to be over-expressed compared with normal pituitary, while PTEN transcripts showed similar levels between the two tissue types. Immunohistochemical expression of phospho-Akt was found to be higher in the tumours than normal pituitaries, while the protein expression of nuclear p27 and PTEN was lower in the adenomas. However, the expression of p27 and Akt were not directly correlated. PTEN sequencing revealed no mutation in the coding region of the gene in pituitary adenomas, and thus we did not locate a cause for the increased phosphorylation of Akt. In summary, we have shown over-expression and activation of the Akt pathway in pituitary tumours, and we speculate that cell-cycle changes observed in such tumours are secondary to these more proximate alterations. Since Akt is a major downstream signalling molecule of growth factor-liganded tyrosine kinase receptors, our data are most compatible with an abnormality at this level as the primary driver of pituitary tumorigenesis.

This article has been cited by other articles:

				V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G. K. Stalla, and M. Theodoropoulou The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells Cancer Res., January 15, 2010; 70(2): 666 - 674. [Abstract] [Full Text] [PDF]

				D Dworakowska, E Wlodek, C A Leontiou, S Igreja, M Cakir, M Teng, N Prodromou, M I Goth, S Grozinsky-Glasberg, M Gueorguiev, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors Endocr. Relat. Cancer, December 1, 2009; 16(4): 1329 - 1338. [Abstract] [Full Text] [PDF]

				T.-W. Noh, H. J. Jeong, M.-K. Lee, T. S. Kim, S. H. Kim, and E. J. Lee Predicting Recurrence of Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4406 - 4413. [Abstract] [Full Text] [PDF]

				A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G. K Stalla, Z. R Cohen, M. Hadani, and I. Shimon Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro Endocr. Relat. Cancer, September 1, 2009; 16(3): 1017 - 1027. [Abstract] [Full Text] [PDF]

				G. Vlotides, O. Cooper, Y.-H. Chen, S.-G. Ren, Y. Greenman, and S. Melmed Heregulin Regulates Prolactinoma Gene Expression Cancer Res., May 15, 2009; 69(10): 4209 - 4216. [Abstract] [Full Text] [PDF]

				D. Dworakowska and A. B Grossman Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review Endocr. Relat. Cancer, March 1, 2009; 16(1): 45 - 58. [Abstract] [Full Text] [PDF]

				Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 301 - 310. [Abstract] [Full Text] [PDF]

				A. Ribeiro-Oliveira Jr, G. Franchi, B. Kola, P. Dalino, S. V. B. Pinheiro, N. Salahuddin, M. Musat, M. I Goth, S. Czirjak, Z. Hanzely, et al. Protein western array analysis in human pituitary tumours: insights and limitations Endocr. Relat. Cancer, December 1, 2008; 15(4): 1099 - 1114. [Abstract] [Full Text] [PDF]